MaxCyte
MXCTNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $1.13 Prior regular-session close from the quote source.
- $1.10–$1.21 Regular-session low and high so far today.
- 2.1M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Jan 11 projected Projected for 2027-01-11 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $0.64–$1.81 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own MXCT if the company reins in cash burn before lumpy partner milestones or instrument sales stall.
MXCT price history
Loading recent earnings…
Investment thesis
What must happen next
MaxCyte’s installed instrument base will produce growing, high-margin recurring revenue through proprietary PAs/consumables and software protocols, providing a steady annuity as placements accumulate.HoldingMateriality: High
MD&A / Business: the company sells proprietary single-use processing assemblies (PAs) that are required for instrument use and says PA demand translates to future revenue tied to instruments placed. If true, revenue will become less lumpy and valuations can reflect predictable recurring cash flows; if false, top-line will remain dependent on one-time instrument sales and valuation will be volatile.
Watch: Commercialization of a superior delivery technology (non-electroporation) by a well-funded instrument OEM that convinces existing partners to switch or to prefer an alternative consumable model.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
MD&A / Business: the company sells proprietary single-use processing assemblies (PAs) that are required for instrument use and says PA.
Open source ↗Strategic Partnership & License (SPL) agreements and milestone / sales‑based payments (including benefits from SeQure’s assay services) can produce lumpy but material upside to revenue and earnings if partner programs advance and reach regulatory/commercial inflection points.HoldingMateriality: High
Business/MD&A: company cites 32 SPL customers and participation in clinical and commercial success of customers through milestone and sales-based payments under SPL agreements. Large SPL milestones or sales-based payments can rapidly improve cash flow and justify a premium multiple; failure of partner programs to progress removes that upside and leaves MaxCyte reliant on slower instrument/consumables growth.
Watch: Partner clinical program failures, regulatory setbacks, or partners electing alternative delivery technologies would remove expected milestone or sales-based payments before they are recognized.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Business/MD&A: company cites 32 SPL customers and participation in clinical and commercial success of customers through milestone and sales-based payments.
Open source ↗The ExPERT platform combined with a broad patent portfolio and field application support creates a technical moat and customer stickiness that should sustain attach rates for consumables and defend pricing.StrengtheningMateriality: Medium
Business/MD&A: platform supported by more than 200 granted U.S. and foreign patents and 100+ pending applications worldwide. A durable moat preserves gross margins and allows MaxCyte to monetize placements over many years; a weak moat would permit competitors to undercut pricing and erode margins and attach rates.
Watch: A competing delivery platform (viral or non-viral) becomes demonstrably superior across the performance dimensions customers care about (efficiency, viability, flexibility, scale), causing customers to swap platforms.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Business/MD&A: platform supported by more than 200 granted U.S. and foreign patents and 100+ pending applications worldwide.
Open source ↗Absent a rapid reduction in operating cash burn or near-term material milestone / partnership cash inflows, MaxCyte will need to raise capital or dilute shareholders, which will materially impair per-share upside.StrengtheningMateriality: Medium
Operating cash flow has been negative and worsening: -$14.783M (2022), -$27.610M (2024), -$34.410M (2025) (trend from filings). If MaxCyte achieves operating cash flow improvement or milestone receipts, equity value can compound; if cash burn persists, future raises will dilute and the premium P/S multiple will compress.
Watch: Receipt of large, previously unannounced milestone payments or upfronts from partners that convert into positive operating cash flow without dilution.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Operating cash flow has been negative and worsening: -$14.783M (2022), -$27.610M (2024), -$34.410M (2025) (trend from filings).
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
MaxCyte’s installed instrument base will produce growing, high-margin recurring revenue through proprietary PAs/consumables and software protocols, providing a steady annuity as placements accumulate. If true, revenue will become less lumpy and valuations can reflect predictable recurring cash flows; if false, top-line will remain dependent on one-time instrument sales and valuation will be volatile.
Strategic Partnership & License (SPL) agreements and milestone / sales‑based payments (including benefits from SeQure’s assay services) can produce lumpy but material upside to revenue and earnings if partner programs advance and reach regulatory/commercial inflection points. Large SPL milestones or sales-based payments can rapidly improve cash flow and justify a premium multiple; failure of partner programs to progress removes that upside and leaves MaxCyte reliant on slower instrument/consumables growth.
The ExPERT platform combined with a broad patent portfolio and field application support creates a technical moat and customer stickiness that should sustain attach rates for consumables and defend pricing. A durable moat preserves gross margins and allows MaxCyte to monetize placements over many years; a weak moat would permit competitors to undercut pricing and erode margins and attach rates.
Absent a rapid reduction in operating cash burn or near-term material milestone / partnership cash inflows, MaxCyte will need to raise capital or dilute shareholders, which will materially impair per-share upside. If MaxCyte achieves operating cash flow improvement or milestone receipts, equity value can compound; if cash burn persists, future raises will dilute and the premium P/S multiple will compress.
All standing thesis claims
Original report summary
the company reins in cash burn before lumpy partner milestones or instrument sales stall.
Bull case and bear case
Bull case and bear case for Maxcyte
Where the evidence on Maxcyte stands: Holding on the latest evidence (Nov 8, 2026). Of its 4 thesis points, 2 strengthening and 2 holding.
Bull case: what the evidence supports
MaxCyte’s installed instrument base will produce growing, high-margin recurring revenue through proprietary PAs/consumables and software protocols, providing a steady annuity as placements accumulate.
Strategic Partnership & License (SPL) agreements and milestone / sales‑based payments (including benefits from SeQure’s assay services) can produce lumpy but material upside to revenue and earnings if partner programs advance and reach regulatory/commercial inflection points.
The ExPERT platform combined with a broad patent portfolio and field application support creates a technical moat and customer stickiness that should sustain attach rates for consumables and defend pricing.
Absent a rapid reduction in operating cash burn or near-term material milestone / partnership cash inflows, MaxCyte will need to raise capital or dilute shareholders, which will materially impair per-share upside.
Bear case: what would count against it
Commercialization of a superior delivery technology (non-electroporation) by a well-funded instrument OEM that convinces existing partners to switch or to prefer an alternative consumable model.
Partner clinical program failures, regulatory setbacks, or partners electing alternative delivery technologies would remove expected milestone or sales-based payments before they are recognized.
A competing delivery platform (viral or non-viral) becomes demonstrably superior across the performance dimensions customers care about (efficiency, viability, flexibility, scale), causing customers to swap platforms.
Thesis-Break Engine
What has broken in Maxcyte’s thesis
Each break OptimistFi flagged on Maxcyte, dated — with what has historically followed the same kind of break across the market, not a forecast for Maxcyte.
- Revenue decline
Across all companies, this kind of break has happened 8,727 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 37% of them trailed it by 10 points or more.
Early warning
The break condition read on the trailing twelve months through Maxcyte’s latest quarterly report, ahead of the annual figure it is written on.
- Revenue decline, trailing 12 months
Across all companies, this kind of early warning has happened 3,039 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 32% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Maxcyte filed an SEC 8-K on 2026-10-14: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Maxcyte filed an SEC 8-K on 2026-08-12: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedDelisting notice or listing-rule failure.
Maxcyte filed an SEC 8-K on 2026-06-16: Delisting notice or listing-rule failure. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Commercialization of a superior delivery technology (non-electroporation) by a well-funded instrument OEM that convinces existing partners to switch or to prefer an alternative consumable model.
- Partner clinical program failures, regulatory setbacks, or partners electing alternative delivery technologies would remove expected milestone or sales-based payments before they are recognized.
- A competing delivery platform (viral or non-viral) becomes demonstrably superior across the performance dimensions customers care about (efficiency, viability, flexibility, scale), causing customers to swap platforms.
- Receipt of large, previously unannounced milestone payments or upfronts from partners that convert into positive operating cash flow without dilution.
MXCT news
Loading headlines…
Financial statements
MXCT income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
MXCT: quick answers
- When does Maxcyte (MXCT) report earnings next?
- Maxcyte's next results are projected for January 11, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 10, 2026. Earnings calendar
- What is MXCT's short interest?
- As of October 30, 2026, 1.6M MXCT shares were sold short, 1.53% of its shares outstanding, down 13.6% from the count before. At the stock's average daily volume that is 1.3 days to cover. FINRA publishes the count twice a month. MXCT short interest history